Akebia Posts $36.9M in Third-Quarter Revenue
AKBA sits 28% above its 52-week low of $0.542.
Summary
Akebia reported third-quarter revenue of $36.9 million, including $14.8 million in Vafseo revenue, and a loss of 5 cents per share. The prior quarter showed a $9.1 million net loss as Auryxia sales fell to generic competition, so any stabilization in the top line matters. The stock is also under a Nasdaq notice after closing below $1.00 for 30 straight business days, with a deadline to regain compliance.
At the time of this announcement, AKBA was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.5M. The 52-week trading range was $0.54 to $2.15. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.